Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatrice Fossati has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Trajectories Associated with Pharmacological Treatment Patterns in Female Adolescents with Anorexia Nervosa: A 12-Month Retrospective Study in Italian Real-World Clinical Practice

    by Pamela Fantozzi, Beatrice Fossati, Fabio Apicella, Vittorio Belmonti, Francesca Ditaranto, Raffaella Tancredi, Pietro Muratori, Valentina Levantini, Sara Calderoni

    Background: Pharmacological treatments are frequently prescribed for adolescents with anorexia nervosa (AN), mainly to address psychiatry comorbidities and associated clinical features, although evidence supporting medication-specific effects remains limited. This retrospective study examined 12-month clinical trajectories associated with different pharmacological treatment patterns in a cohort of female adolescents with AN admitted to a tertiary university hospital. Methods: Clinical records of 102 female patients aged 12–18 years with AN were retrospectively reviewed. Participants were first classified according to whether they received any pharmacological treatment and were subsequently divided into six groups: no medication, antidepressants, antipsychotics, mood stabilizers, combination therapy, and medication switching. Body mass index (BMI), Clinical Global Impression—Severity (CGI-S), Children’s Global Assessment Scale (C-GAS), and item 40 of the Structured Interview for Anorexic and Bulimic Syndromes—Expert Form (SIAB-EX) were evaluated at admission (T0, before treatment initiation), at 6-month follow-up (T1), and at 12-month follow-up (T2). Results: BMI improved significantly over time across all treatment groups. Compared with participants who received any form of pharmacological treatment, the non-medicated group exhibited a significantly greater increase in mean CGI-S scores and significantly greater reductions in mean C-GAS and SIAB-EX scores. Baseline comparison among the six treatment groups showed significant differences in CGI-S, C-GAS, and SIAB-EX item 40 scores, indicating that the groups were not fully comparable in terms of initial clinical severity, global functioning, and physical hyperactivity. Patients in the medication-switching group generally showed smaller improvements, whereas findings in the mood-stabilizer group should be interpreted cautiously because of the very small sample size. Conclusions: In this real inpatients cohort, adolescents with AN showed clinical improvement over 12 months across different pharmacological treatment patterns. However, baseline differences between groups and the non-randomized retrospective design preclude causal conclusions regarding medication-specific effectiveness. These findings should be interpreted as descriptive clinical trajectories associated with treatment patterns selected in routine care. Further prospective studies with standardized treatment data and adequately powered subgroups are needed.

  • Open Access

    How COVID-19 Phases Have Impacted Psychiatric Risk: A Retrospective Study in an Emergency Care Unit for Adolescents

    by Maria Mucci, Francesca Lenzi, Giulia Maria D'Acunto, Marisa Gazzillo, Ilaria Accorinti, Silvia Boldrini, Giacomo Distefano, Francesca Falcone, Beatrice Fossati, Roberto Giurdanella Annina, et al.

    Dramatic events during the COVID-19 pandemic have acutely impacted the psychosocial environment worldwide, with negative implications for mental health, particularly for more vulnerable children and adolescents with severe psychiatric illnesses. Some data suggest that the pandemic waves may have produced different psychopathological consequences, further worsening in the second phase of the pandemic, compared to those in the first lockdown, soon after March 2020. To test the hypothesis of a further worsening of psychiatric consequences of COVID-19 in the second lockdown compared to the first lockdown, we focused our analysis on a consecutive sample of youth referred to a psychiatric emergency unit for acute mental disorders in the time period between March 2019–March 2021. The sample, consisting of 241 subjects (123 males and 118 females, ranging in age from 11 to 17 years), was divided into three groups: Pre-Lockdown Group (PLG, 115 patients); First Lockdown Group (FLG, 65 patients); and Second Lockdown Group (SLG, 61 patients). Patients in the SLG presented more frequently with non-suicidal self-injuries (NSSIs), suicidal ideation, and suicidal behavior, while no significant differences in self-harm were found between PLG and FLG. Eating disorders were more frequent in both the FLG and SLG, compared to the PLG, while sleep problems were higher only in the SLG. Furthermore, patients in the SLG presented with more frequent psychological maltreatments and neglect, as well as with psychiatric disorders in the parents. Adverse traumatic experiences and internalizing disorders were significantly associated with an increased risk of suicidality. Intellectual disability was less represented from the PLG to SLG, and similarly, the rate of ADHD was lower in the SLG. No differences were found for the other psychiatric diagnoses. This information may be helpful for a better understanding and management of adolescents with severe emotional and behavioral disorders after the exposure to long-lasting collective traumas.


  • Open Access

    Neuroleptic Malignant Syndrome in Children with Autism Spectrum Disorder (ASD): A Case Report and Brief Review of Recent Literature

    by Stefano Berloffa, Claudia Dosi, Benedetta Tascini, Beatrice Fossati, Ilaria Lupetti, Gabriele Masi

    Neuroleptic malignant syndrome (NMS) is a rare, life-threatening, idiosyncratic adverse reaction to antipsychotic drugs. Despite the increasing rates in the prescription of antipsychotics in pediatric patients with autism spectrum disorder (ASD), little is known about the occurrence and hallmarks of NMS in this specific population. NMS appears to be part of the larger catatonia domain, based on the frequent relationship between ASD and catatonia, on the shared, when not overlapping, clinical features with malignant catatonia, and on the effectiveness of catatonia treatments on the NMS/MC symptoms. The intrinsic difficulties of exploring NMS in ASD in controlled studies accounts for the subsequent lack of available information. Based on recent reports and on our case report, clinical features of NMS in the pediatric ASD population appear to be the same as the non-ASD population. Further studies are needed to confirm these results.